Quest Diagnostics (DGX) stock
Last close $259.09 on 2026-11-19 (-0.23%) · Sector: Healthcare
Quest Diagnostics is one of the largest medical laboratory companies in the United States, running blood, urine, and other tests that doctors, hospitals, and patients rely on to check health. It makes most of its money by charging for these lab tests, billed to insurers, employers, hospitals, and patients, and it also sells related health information services.
Quest's business is growing steadily, with revenue up 9.2% and profit rising in recent quarters. The stock has done well, returning 38.1% over the past year versus 9.7% for the S&P 500, and it trades above both its 50-day and 200-day averages. Insiders have sold shares over the last 90 days and made no purchases, and the stock has risen the day after each of its last five earnings reports. The stock is also more jumpy than the overall market, so expect bigger price swings.
Key numbers
- Market cap: $29.0B
- Revenue (last 12 months): $11.85B
- Revenue growth: +9.2%
- Gross margin: 33.0%
- Operating margin: 14.6%
- P/E: 25.8
- P/S: 2.4
- Debt to equity: 0.73
- Current ratio: 1.70
Quality score
Overall 37/100 · growth 37 · profitability 38 · financial health 44 · value 30
Performance and risk
1-year return +38.1% vs S&P 500 +9.7% · volatility 24.1% (S&P 500 13.8%) · largest drop -11.9% · beta -0.06
Stock move the day after earnings
- 2026-01-12: +2.3%
- 2026-02-10: +7.4%
- 2026-04-21: +4.4%
- 2026-07-23: +8.6%
- 2026-10-22: +1.8%
Insider trades (12 months)
Bought $0.0M · sold $48.9M
DGX stock research · DGX options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.